Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 109 entries
Sorted by: Best Match Show Resources per page
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis.

Clinical ophthalmology (Auckland, N.Z.)

McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G.
PMID: 28652694
Clin Ophthalmol. 2017 Jun 08;11:1089-1097. doi: 10.2147/OPTH.S131830. eCollection 2017.

PURPOSE: Two individual phase 3 conjunctival allergen challenge (CAC) studies of similar design have assessed the efficacy and safety of olopatadine hydrochloride (HCl) 0.77% for the treatment of allergic conjunctivitis. The purpose of this study is to evaluate the...

Cite
McLaurin E, Bergmann M, Narvekar A, et al. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clin Ophthalmol. 2017;11:1089-1097doi: 10.2147/OPTH.S131830.
McLaurin, E., Bergmann, M., Narvekar, A., Adewale, A., Gomes, P., & Torkildsen, G. (2017). Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical ophthalmology (Auckland, N.Z.), 111089-1097. https://doi.org/10.2147/OPTH.S131830
McLaurin, Eugene, et al. "Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis." Clinical ophthalmology (Auckland, N.Z.) vol. 11 (2017): 1089-1097. doi: https://doi.org/10.2147/OPTH.S131830
McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clin Ophthalmol. 2017 Jun 08;11:1089-1097. doi: 10.2147/OPTH.S131830. eCollection 2017. PMID: 28652694; PMCID: PMC5472412.
Copy Download .nbib Format: NLM
Melanonychia and skin hyperpigmentation with hydroxyurea therapy.

Indian journal of pharmacology

Koley S, Choudhary S, Salodkar A.
PMID: 20606846
Indian J Pharmacol. 2010 Feb;42(1):60-1. doi: 10.4103/0253-7613.62394.

No abstract available.

Cite
Koley S, Choudhary S, Salodkar A. Melanonychia and skin hyperpigmentation with hydroxyurea therapy. Indian J Pharmacol. 2010;42(1):60-1doi: 10.4103/0253-7613.62394.
Koley, S., Choudhary, S., & Salodkar, A. (2010). Melanonychia and skin hyperpigmentation with hydroxyurea therapy. Indian journal of pharmacology, 42(1), 60-1. https://doi.org/10.4103/0253-7613.62394
Koley, Sankha, et al. "Melanonychia and skin hyperpigmentation with hydroxyurea therapy." Indian journal of pharmacology vol. 42,1 (2010): 60-1. doi: https://doi.org/10.4103/0253-7613.62394
Koley S, Choudhary S, Salodkar A. Melanonychia and skin hyperpigmentation with hydroxyurea therapy. Indian J Pharmacol. 2010 Feb;42(1):60-1. doi: 10.4103/0253-7613.62394. PMID: 20606846; PMCID: PMC2885649.
Copy Download .nbib Format: NLM
Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis.

Health and quality of life outcomes

Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M.
PMID: 20836888
Health Qual Life Outcomes. 2010 Sep 13;8:99. doi: 10.1186/1477-7525-8-99.

PURPOSE: It is vital to understand the associations between the medication event monitoring systems (MEMS) and self-reported questionnaires (SRQs) because both are often used to measure medication adherence and can produce different results. In addition, the economic implication of...

Cite
Shi L, Liu J, Fonseca V, et al. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;8:99doi: 10.1186/1477-7525-8-99.
Shi, L., Liu, J., Fonseca, V., Walker, P., Kalsekar, A., & Pawaskar, M. (2010). Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health and quality of life outcomes, 899. https://doi.org/10.1186/1477-7525-8-99
Shi, Lizheng, et al. "Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis." Health and quality of life outcomes vol. 8 (2010): 99. doi: https://doi.org/10.1186/1477-7525-8-99
Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010 Sep 13;8:99. doi: 10.1186/1477-7525-8-99. PMID: 20836888; PMCID: PMC2944346.
Copy Download .nbib Format: NLM
Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient.

Indian journal of sexually transmitted diseases and AIDS

Koley S, Saoji V, Salodkar A.
PMID: 21938132
Indian J Sex Transm Dis AIDS. 2009 Jul;30(2):109-11. doi: 10.4103/0253-7184.62769.

Herpes Zoster (HZ) lesions are well known to heal with keloids. As immunity plays an important role in the development of abnormal scars and keloids, the latter is unusual in HIV where immunity is low. We report a rare...

Cite
Koley S, Saoji V, Salodkar A. Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient. Indian J Sex Transm Dis AIDS. 2009;30(2):109-11doi: 10.4103/0253-7184.62769.
Koley, S., Saoji, V., & Salodkar, A. (2009). Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient. Indian journal of sexually transmitted diseases and AIDS, 30(2), 109-11. https://doi.org/10.4103/0253-7184.62769
Koley, Sankha, et al. "Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient." Indian journal of sexually transmitted diseases and AIDS vol. 30,2 (2009): 109-11. doi: https://doi.org/10.4103/0253-7184.62769
Koley S, Saoji V, Salodkar A. Unusual formation of keloids after each episode of recurrent herpes zoster in an HIV positive patient. Indian J Sex Transm Dis AIDS. 2009 Jul;30(2):109-11. doi: 10.4103/0253-7184.62769. PMID: 21938132; PMCID: PMC3168053.
Copy Download .nbib Format: NLM
A versatile LC-MS/MS approach for comprehensive, quantitative analysis of central metabolic pathways.

Wellcome open research

Walvekar A, Rashida Z, Maddali H, Laxman S.
PMID: 30345389
Wellcome Open Res. 2018 Sep 20;3:122. doi: 10.12688/wellcomeopenres.14832.1. eCollection 2018.

Liquid chromatography-mass spectrometry (LC-MS/MS) based approaches are widely used for the identification and quantitation of specific metabolites, and are a preferred approach towards analyzing cellular metabolism. Most methods developed come with specific requirements such as unique columns, ion-pairing reagents...

Cite
Walvekar A, Rashida Z, Maddali H, et al. A versatile LC-MS/MS approach for comprehensive, quantitative analysis of central metabolic pathways. Wellcome Open Res. 2018;3:122doi: 10.12688/wellcomeopenres.14832.1.
Walvekar, A., Rashida, Z., Maddali, H., & Laxman, S. (2018). A versatile LC-MS/MS approach for comprehensive, quantitative analysis of central metabolic pathways. Wellcome open research, 3122. https://doi.org/10.12688/wellcomeopenres.14832.1
Walvekar, Adhish, et al. "A versatile LC-MS/MS approach for comprehensive, quantitative analysis of central metabolic pathways." Wellcome open research vol. 3 (2018): 122. doi: https://doi.org/10.12688/wellcomeopenres.14832.1
Walvekar A, Rashida Z, Maddali H, Laxman S. A versatile LC-MS/MS approach for comprehensive, quantitative analysis of central metabolic pathways. Wellcome Open Res. 2018 Sep 20;3:122. doi: 10.12688/wellcomeopenres.14832.1. eCollection 2018. PMID: 30345389; PMCID: PMC6171562.
Copy Download .nbib Format: NLM
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

Value in health regional issues

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H.
PMID: 29702919
Value Health Reg Issues. 2014 May;3:136-145. doi: 10.1016/j.vhri.2014.04.005. Epub 2014 May 21.

OBJECTIVES: Japan has one of the highest endemic rates of hepatitis C virus (HCV) infection. Treatments in Japan are currently limited to interferon-alfa-based regimens, which are associated with tolerability and efficacy issues. A novel regimen combining two oral HCV...

Cite
McEwan P, Ward T, Webster S, et al. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value Health Reg Issues. 2014;3:136-145doi: 10.1016/j.vhri.2014.04.005.
McEwan, P., Ward, T., Webster, S., Yuan, Y., Kalsekar, A., Broglio, K., Kamae, I., Quintana, M., Berry, S. M., Kobayashi, M., Inoue, S., Tang, A., & Kumada, H. (2014). Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in health regional issues, 3136-145. https://doi.org/10.1016/j.vhri.2014.04.005
McEwan, Phil, et al. "Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b." Value in health regional issues vol. 3 (2014): 136-145. doi: https://doi.org/10.1016/j.vhri.2014.04.005
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value Health Reg Issues. 2014 May;3:136-145. doi: 10.1016/j.vhri.2014.04.005. Epub 2014 May 21. PMID: 29702919.
Copy Download .nbib Format: NLM
Depression and Epilepsy: We Are No Longer One Direction.

Epilepsy currents

Salpekar J.
PMID: 29225525
Epilepsy Curr. 2017 Jul-Aug;17(4):223-224. doi: 10.5698/1535-7597.17.4.223.

No abstract available.

Cite
Salpekar J. Depression and Epilepsy: We Are No Longer One Direction. Epilepsy Curr. 2017;17(4):223-224doi: 10.5698/1535-7597.17.4.223.
Salpekar, J. (2017). Depression and Epilepsy: We Are No Longer One Direction. Epilepsy currents, 17(4), 223-224. https://doi.org/10.5698/1535-7597.17.4.223
Salpekar, Jay. "Depression and Epilepsy: We Are No Longer One Direction." Epilepsy currents vol. 17,4 (2017): 223-224. doi: https://doi.org/10.5698/1535-7597.17.4.223
Salpekar J. Depression and Epilepsy: We Are No Longer One Direction. Epilepsy Curr. 2017 Jul-Aug;17(4):223-224. doi: 10.5698/1535-7597.17.4.223. PMID: 29225525; PMCID: PMC5716114.
Copy Download .nbib Format: NLM
Seizures, Nonepileptic Events, Trauma, Anxiety, or All of the Above.

Epilepsy currents

Salpekar J.
PMID: 30838927
Epilepsy Curr. 2019 Jan;19(1):29-30. doi: 10.1177/1535759718822842. Epub 2019 Jan 30.

Psychiatric Comorbidity and Traumatic Brain Injury Attribution in Patients With Psychogenic Nonepileptic or Epileptic Seizures: A Multicenter Study of US Veterans Salinsky M, Rutecki P, Parko K, Goy E, Storzbach D, O'Neil M, Binder L, Joos S. Epilepsia. 2018....

Cite
Salpekar J. Seizures, Nonepileptic Events, Trauma, Anxiety, or All of the Above. Epilepsy Curr. 2019;19(1):29-30doi: 10.1177/1535759718822842.
Salpekar, J. (2019). Seizures, Nonepileptic Events, Trauma, Anxiety, or All of the Above. Epilepsy currents, 19(1), 29-30. https://doi.org/10.1177/1535759718822842
Salpekar, Jay. "Seizures, Nonepileptic Events, Trauma, Anxiety, or All of the Above." Epilepsy currents vol. 19,1 (2019): 29-30. doi: https://doi.org/10.1177/1535759718822842
Salpekar J. Seizures, Nonepileptic Events, Trauma, Anxiety, or All of the Above. Epilepsy Curr. 2019 Jan;19(1):29-30. doi: 10.1177/1535759718822842. Epub 2019 Jan 30. PMID: 30838927; PMCID: PMC6610371.
Copy Download .nbib Format: NLM
A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis.

Clinical ophthalmology (Auckland, N.Z.)

Pepose JS, Narvekar A, Liu W, Haque R.
PMID: 30962674
Clin Ophthalmol. 2019 Mar 21;13:535-544. doi: 10.2147/OPTH.S191275. eCollection 2019.

PURPOSE: To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically suspected acute viral conjunctivitis.PATIENTS AND METHODS: This was a randomized, double-masked, parallel-group, vehicle-controlled study. Adults with a...

Cite
Pepose JS, Narvekar A, Liu W, et al. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol. 2019;13:535-544doi: 10.2147/OPTH.S191275.
Pepose, J. S., Narvekar, A., Liu, W., & Haque, R. (2019). A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clinical ophthalmology (Auckland, N.Z.), 13535-544. https://doi.org/10.2147/OPTH.S191275
Pepose, Jay S, et al. "A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis." Clinical ophthalmology (Auckland, N.Z.) vol. 13 (2019): 535-544. doi: https://doi.org/10.2147/OPTH.S191275
Pepose JS, Narvekar A, Liu W, Haque R. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol. 2019 Mar 21;13:535-544. doi: 10.2147/OPTH.S191275. eCollection 2019. PMID: 30962674; PMCID: PMC6433103.
Copy Download .nbib Format: NLM
The long view of epilepsy and depression in pediatrics.

Developmental medicine and child neurology

Salpekar JA.
PMID: 31769020
Dev Med Child Neurol. 2020 May;62(5):543-544. doi: 10.1111/dmcn.14416. Epub 2019 Nov 25.

No abstract available.

Cite
Salpekar JA. The long view of epilepsy and depression in pediatrics. Dev Med Child Neurol. 2019;62(5):543-544doi: 10.1111/dmcn.14416.
Salpekar, J. A. (2020). The long view of epilepsy and depression in pediatrics. Developmental medicine and child neurology, 62(5), 543-544. https://doi.org/10.1111/dmcn.14416
Salpekar, Jay A. "The long view of epilepsy and depression in pediatrics." Developmental medicine and child neurology vol. 62,5 (2020): 543-544. doi: https://doi.org/10.1111/dmcn.14416
Salpekar JA. The long view of epilepsy and depression in pediatrics. Dev Med Child Neurol. 2020 May;62(5):543-544. doi: 10.1111/dmcn.14416. Epub 2019 Nov 25. PMID: 31769020.
Copy Download .nbib Format: NLM
Interplay of global multi-scale human mobility, social distancing, government interventions, and COVID-19 dynamics.

medRxiv : the preprint server for health sciences

Adiga A, Wang L, Sadilek A, Tendulkar A, Venkatramanan S, Vullikanti A, Aggarwal G, Talekar A, Ben X, Chen J, Lewis B, Swarup S, Tambe M, Marathe M.
PMID: 32577671
medRxiv. 2020 Aug 22; doi: 10.1101/2020.06.05.20123760.

This work quantifies mobility changes observed during the different phases of the pandemic world-wide at multiple resolutions -- county, state, country -- using an anonymized aggregate mobility map that captures population flows between geographic cells of size 5 km

Cite
Adiga A, Wang L, Sadilek A, et al. Interplay of global multi-scale human mobility, social distancing, government interventions, and COVID-19 dynamics. medRxiv. 2020;doi: 10.1101/2020.06.05.20123760.
Adiga, A., Wang, L., Sadilek, A., Tendulkar, A., Venkatramanan, S., Vullikanti, A., Aggarwal, G., Talekar, A., Ben, X., Chen, J., Lewis, B., Swarup, S., Tambe, M., & Marathe, M. (2020). Interplay of global multi-scale human mobility, social distancing, government interventions, and COVID-19 dynamics. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.06.05.20123760
Adiga, Aniruddha, et al. "Interplay of global multi-scale human mobility, social distancing, government interventions, and COVID-19 dynamics." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.06.05.20123760
Adiga A, Wang L, Sadilek A, Tendulkar A, Venkatramanan S, Vullikanti A, Aggarwal G, Talekar A, Ben X, Chen J, Lewis B, Swarup S, Tambe M, Marathe M. Interplay of global multi-scale human mobility, social distancing, government interventions, and COVID-19 dynamics. medRxiv. 2020 Aug 22; doi: 10.1101/2020.06.05.20123760. PMID: 32577671; PMCID: PMC7302225.
Copy Download .nbib Format: NLM
Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?.

BMC pediatrics

Anvekar A, Athikarisamy S, Rao S, Gill A, Nathan E, Doherty D, Lam G.
PMID: 34856950
BMC Pediatr. 2021 Dec 02;21(1):540. doi: 10.1186/s12887-021-03027-x.

BACKGROUND: Poor weight gain in the first few weeks of life has been studied as a predictor of retinopathy of prematurity (ROP). Our aim was to assess whether time taken to regain birthweight (BW) be used as an additional...

Cite
Anvekar A, Athikarisamy S, Rao S, et al. Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?. BMC Pediatr. 2021;21(1):540doi: 10.1186/s12887-021-03027-x.
Anvekar, A., Athikarisamy, S., Rao, S., Gill, A., Nathan, E., Doherty, D., & Lam, G. (2021). Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?. BMC pediatrics, 21(1), 540. https://doi.org/10.1186/s12887-021-03027-x
Anvekar, Ajay, et al. "Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?." BMC pediatrics vol. 21,1 (2021): 540. doi: https://doi.org/10.1186/s12887-021-03027-x
Anvekar A, Athikarisamy S, Rao S, Gill A, Nathan E, Doherty D, Lam G. Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?. BMC Pediatr. 2021 Dec 02;21(1):540. doi: 10.1186/s12887-021-03027-x. PMID: 34856950; PMCID: PMC8638437.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 109 entries